Serial assessment of the molecular characteristics of EGFR-mutant NSCLC with each line of therapy will assist in understanding the evolution of on- and off-target mechanisms of resistance and can help guide the development of new therapeutic strategies for patients with resistant disease. Here, EGFR is linked to non-small cell lung carcinoma.